• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Saphris?





















Yet another product that Merck botched the launch of by disregarding the advise of those people that knew what was going on. Schering was preparing for the launch at the merger and Merck went in and changed everything that had been planned.